GLOBAL BIOENERGIES launches a private placement
(Thomson Reuters ONE) -
This document may not be distributed, directly or indirectly, in the United
States, Canada, Australia or Japan.
GLOBAL BIOENERGIES launches a private placement
Evry, 20 January 2016 - Global Bioenergies (Alternext Paris: ALGBE) ("the
Company") today announced that it is launching an increase in its share capital
through the issue of new ordinary shares, without preferential subscription
rights, to qualified investors, pursuant to the eighth resolution of the
Combined General Shareholders Meeting held on 3 June 2015, in the amount of
approximately ?6 million, i.e. approximately 10% of the Company's share capital.
Application will be made for the new shares to be admitted for trading on
Euronext Paris.
The funds will be raised in accordance with Article L.411-2 II of the French
Monetary and Financial Code (Code monétaire et financier) (the "Private
Placement"), from domestic and international qualified investors, notably
excluding Canada, Australia and Japan. They will be used to further the
development of the isobutene process and to launch commercial roll-out.
The CM-CIC Investissement SCR and CM-CIC Innovation funds have undertaken, under
certain conditions, to subscribe to the capital increase for a total of 18% of
the funds to be raised, in an amount not to exceed ?1.8 million, and at a
maximum price of ?25.5 per share. The FCPIs BioSanté 2013, BioSanté 2014,
Masseran Innovation VI and Seventure Preference Innovation 2013
high-tech mutual funds have undertaken, under certain conditions, to subscribe
to the capital increase for a total amount of ?1.7 million, at a maximum price
of ?25.5 per share.
According to the terms of the eighth resolution of the Combined General
Shareholders Meeting held on 3 June 2015, the issue price of the new shares will
be at least equal to the weighted average price of the Company's share on the
Euronext Paris Alternext market in the last three trading sessions prior to
setting the issue price, which may be reduced by a maximum discount of 20%,
within the limit of 17,5% of the Company's share capital, i.e. a maximum of
504 039 new shares.
Marc Delcourt, CEO at Global Bioenergies says: "The funds raised through this
private placement will enable the Company to switch to full-scale commercial
roll-out. We are expecting to sign several significant industrial agreements
starting in 2016."
The Private Placement is being conducted by Gilbert Dupont (Paris) and Baader
Bank AG (Munich) as joint lead managers and joint bookrunners. The issue does
not require registration with the French financial markets authority (AMF) or
publication of a prospectus.
The final terms and results of the Private Placement will be announced as soon
as possible.
Legal notice
This document may not be distributed, directly or indirectly, in or into the
United States. This document is not an offer of securities for sale nor the
solicitation of an offer to purchase securities in the United States. Securities
may not be offered or sold in the United States absent registration under the
U.S. Securities Act of 1933, as amended, or an exemption from registration. The
shares of the Company have not been and will not be registered under the U.S.
Securities Act, and the Company does not intend to make a public offer of its
securities in the United States.
About GLOBAL BIOENERGIES
Global Bioenergies is one of the few companies worldwide, and the only one in
Europe, that is developing a process to convert renewable resources into
hydrocarbons through fermentation. The Company initially focused its efforts on
the production of isobutene, one of the most important petrochemical building
blocks that can be converted into fuels, plastics, organic glass and elastomers.
Global Bioenergies continues to improve the performances of its process,
operates its industrial pilot, has begun the construction of its demo plant in
Germany, and is preparing the first full-scale plant through a joint venture
with Cristal Union, named IBN-One. The company also replicated its achievement
to propylene and butadiene, two members of the gaseous olefins family, key
molecules at the heart of petrochemical industry. Global Bioenergies is listed
on Alternext, Euronext Paris (FR0011052257 - ALGBE) and on the Alternext Oseo
Innovation index.
Should you like to be kept informed, subscribe to our news feed on www.global-
bioenergies.com
Follow us on Twitter: (at)GlobalBioenergi
Contact
GLOBAL BIOENERGIES
François-Henri Sahakian
Chief Financial Officer
Phone: +33 (0)1 64 98 20 50
Email: invest(at)global-bioenergies.com
This document may not be distributed, directly or indirectly, in the United
States, Canada, Australia or Japan.
PRESS RELEASE:
http://hugin.info/166909/R/1980269/725406.pdf
This announcement is distributed by GlobeNewswire on behalf of
GlobeNewswire clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: GLOBAL BIOENERGIES via GlobeNewswire
[HUG#1980269]
Unternehmensinformation / Kurzprofil:
Datum: 20.01.2016 - 17:45 Uhr
Sprache: Deutsch
News-ID 445463
Anzahl Zeichen: 6352
contact information:
Town:
Evry
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 278 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"GLOBAL BIOENERGIES launches a private placement"
steht unter der journalistisch-redaktionellen Verantwortung von
GLOBAL BIOENERGIES (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
